Assessing Alnylam Pharmaceuticals’ (ALNY) Valuation After Its Inclusion in the Nasdaq 100 Index

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...
Le Lézard

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing ...

Vir Biotechnology, Inc. today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for ...

Sutro Biopharma (STRO) Receives a Buy from Piper Sandler

Detailed price information for Sutro Biopharma Inc (STRO-Q) from The Globe and Mail including charting and trades.

Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...
TipRanks on MSN

Insmed price target raised to $230 from $216 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Insmed (INSM) to $230 from $216 and keeps an Overweight rating on the shares. The firm views ...